文献速递临床试验与 GCP

极早产儿气管内布地奈德联合肺表面活性物质:PLUSS随机临床试验

Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

这项双盲随机临床试验在4国21个新生儿病房纳入胎龄小于28周、生后48小时内需机械通气或非侵入性呼吸支持并临床决定使用肺表面活性物质的极早产儿,1:1随机接受布地奈德0.25 mg/kg混合肺表面活性物质(猪肺磷脂α)或单用肺表面活性物质。主要结局为矫正胎龄36周无支气管肺发育不良(BPD)生存,布地奈德联合组25.6% vs 单用组22.6%(校正风险差2.7%,95%CI -2.1%至7.4%)。作者认为早期气管内布地奈德对无BPD生存可能几乎无影响。

要点

  • 布地奈德联合肺表面活性物质组无BPD生存25.6%,单用肺表面活性物质组22.6%。
  • 校正风险差2.7%(95%CI -2.1%至7.4%),未达统计学显著。
  • 矫正胎龄36周时,两组存活率分别为83.2%和80.6%,存活者中BPD诊断率分别为69.3%和71.9%。

核心结论

  • 在接受肺表面活性物质治疗呼吸窘迫综合征的极早产儿中,早期气管内布地奈德对无BPD生存可能几乎无影响。

研究设计与样本

  • 双盲随机临床试验,在4个国家(澳大利亚、新西兰、加拿大、新加坡)的21个新生儿病房开展。
  • 纳入胎龄小于28周、生后小于48小时、接受机械通气(不论呼吸机参数或氧需求)或接受非侵入性呼吸支持且临床决定使用肺表面活性物质的婴儿。
  • 招募时间为2018年1月至2023年3月,最后一名参与者于2023年8月出院。
  • 婴儿按1:1随机分配接受布地奈德0.25 mg/kg混合肺表面活性物质(猪肺磷脂α)经气管插管或细导管给药,或单用肺表面活性物质。
  • 主要分析纳入1059名婴儿,布地奈德联合肺表面活性物质组524名,单用肺表面活性物质组535名。

主要发现

  • 总体婴儿平均胎龄25.6周(SD 1.3周),平均出生体重775 g(SD 197 g),586名(55.3%)为男性。
  • 无BPD生存:布地奈德联合肺表面活性物质组134名(25.6%) vs 单用肺表面活性物质组121名(22.6%),校正风险差2.7%(95%CI -2.1%至7.4%)。
  • 矫正胎龄36周时存活:布地奈德联合肺表面活性物质组83.2% vs 单用肺表面活性物质组80.6%。
  • 存活者中诊断BPD:布地奈德联合肺表面活性物质组69.3% vs 单用肺表面活性物质组71.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Bronchopulmonary dysplasia (BPD) is a common adverse outcome in extremely preterm infants born at less than 28 weeks' gestation. Systemic corticosteroids are effective against BPD but may be associated with adverse outcomes. Corticosteroids given directly into the lungs may be effective and safer. OBJECTIVE: To investigate the effectiveness of early intratracheal corticosteroid administration on survival free of BPD in extremely preterm infants. DESIGN, SETTING, AND PARTICIPANTS: Double-blind randomized clinical trial conducted in 21 neonatal units in 4 countries (Australia, New Zealand, Canada, and Singapore), enrolling infants born at less than 28 weeks' gestation and less than 48 hours old who were mechanically ventilated (regardless of ventilator settings or oxygen requirements) or who were receiving noninvasive respiratory support and had a clinical decision to treat with surfactant. Recruitment occurred from January 2018 to March 2023. The last participant was discharged from the hospital in August 2023. INTERVENTIONS: Infants were randomly allocated (1:1) to receive budesonide, 0.25 mg/kg, mixed with surfactant (poractant alfa), administered via an endotracheal tube or thin catheter, or surfactant only. MAIN OUTCOMES AND MEASURES: The primary outcome was survival free of BPD at 36 weeks' postmenstrual age. There were 15 secondary outcomes, including the 2 components of the primary outcome (survival at 36 weeks and BPD among survivors), and 9 predefined safety outcomes (adverse events). RESULTS: The primary analysis included 1059 infants, 524 in the budesonide and surfactant group and 535 in the surfactant-only group. Overall, infants had a mean gestational age of 25.6 weeks (SD, 1.3 weeks) and a mean birth weight of 775 g (SD, 197 g); 586 (55.3%) were male. Survival free of BPD occurred in 134 infants (25.6%) in the budesonide and surfactant group and 121 infants (22.6%) in the surfactant-only group (adjusted risk difference, 2.7% [95% CI, -2.1% to 7.4%]). At 36 weeks' postmenstrual age, 83.2% of infants were alive in the budesonide and surfactant group and 80.6% in the surfactant-only group. Of these, 69.3% and 71.9% were diagnosed with BPD, respectively. CONCLUSIONS AND RELEVANCE: In extremely preterm infants receiving surfactant for respiratory distress syndrome, early intratracheal budesonide may have little to no effect on survival free of BPD. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12617000322336.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Manley BJ, Kamlin COF, Donath SM, et al. Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial. JAMA. 2024. PMID: 39527075. doi:10.1001/jama.2024.17380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。